A Closer Look at FY2Q26 (July) ResultsRevenueTotal revenue of $800.6 million (up 9% y/y) which beat both the company’s guidance range for revenue of between $777.0 million and $781.0 million and the Street’s estimate of $780.1 million driven by strength in its direct sales channel, particularly wit
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will also participate...
Two Directors at Coty Inc bought 290,000 shares at between 3.840USD and 3.916USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
MISSION PRODUCE® to Release Fiscal Third Quarter 2025 Financial Results on Monday, September 8, 2025 OXNARD, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today announced it will release its financial results for the fiscal third quarter ended July 31, 2025 after the market closes on Monday, September 8, 2025. The Company will host a conference call and webcast to discuss its financial results at 5:00 PM Eastern Time on the same day. Conference Call De...
Erasca Reports Second Quarter 2025 Business Updates and Financial Results Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerc...
Mission Produce® Plans Ahead for Continued Global Growth; Celebrates Legacy of Juan Wiesner, President of Central & South America Ahead of Retirement from Company and Announces Successor OXNARD, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today announced that Juan Wiesner, Mission’s President of Central and South America, will retire from the Company effective November 1, 2025, following 14 years of dedicated leadership. As part of the Company’s strat...
Compass Diversified Announces Extended Forbearance WESTPORT, Conn., July 28, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) ("CODI" or the “Company”) announced today that on July 25, 2025, the Company and its lender group entered into a second forbearance agreement, extending the prior forbearance period until October 24, 2025. CODI’s lenders have further increased the amount of availability on the Company's $100 million revolving credit facility, increasing it from $40 million to $60 million during the forbearance period. CODI originally entered into a forbearance agreement w...
Compass Diversified Declares Second Quarter 2025 Distributions on Series A, B and C Preferred Shares WESTPORT, Conn., July 02, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution for each of its three preferred share series. This announcement underscores that in the wake of its ongoing investigation of Lugano, the Company’s diversified business model supports its continued ability to generate strong cash flow. ...
Mission Produce® Appoints Laura Flanagan to Board of Directors OXNARD, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados, today announced the appointment of Laura Flanagan to its board of directors, effective June 30, 2025. Flanagan is appointed as an independent Class III director with a term expiring at the Company’s 2026 Annual Meeting of Stockholders. In connection with this appointment, Mission Produce’s board of directors has increased the size of the...
Compass Diversified Provides an Update on its Financial Statements Amid the Ongoing Investigation into Lugano Holding, Inc. WESTPORT, Conn., June 25, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today disclosed non-reliance on its financial statements for fiscal years 2022 and 2023 amid an ongoing investigation into its subsidiary Lugano Holding, Inc. (“Lugano”). This follows CODI’s May 7 disclosure concerning non-reliance on its 2024 financial statements. As previously disclosed, the investigation has preliminarily identified irregularities in Lugano’s financing, ac...
Mission Produce® Announces Fiscal 2025 Second Quarter Financial Results Achieved record fiscal second quarter revenue driven by the Marketing & Distribution segment OXNARD, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today reported its financial results for the fiscal second quarter ended April 30, 2025. Fiscal Second Quarter 2025 Financial Overview: Total revenue increased 28% to $380.3 million compared to the same period last yearNet income of ...
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.